---
title: "10:00 ET\n\t\t\t\n\t\t\t\n\t\t\t\tINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO"
description: "Pomerantz Law Firm has filed a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) for alleged securities fraud and unlawful business practices. Investors who suffered losses are encouraged to c"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259219887.md"
published_at: "2025-09-28T14:02:36.000Z"
---

# 10:00 ET
			
			
				INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

> Pomerantz Law Firm has filed a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) for alleged securities fraud and unlawful business practices. Investors who suffered losses are encouraged to contact the firm by September 30, 2025, to be appointed as Lead Plaintiff. The lawsuit follows Novo Nordisk's significant sales outlook reduction for 2025, which led to a 21.83% drop in its ADR price on July 29, 2025. Pomerantz LLP specializes in corporate and securities class litigation, advocating for victims of corporate misconduct.

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at \[email protected\] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

**You have until September 30, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Novo Nordisk securities during the Class Period. A copy of the Complaint can be obtained at** **www.pomerantzlaw.com** **.**

**\[Click here for information about joining the class action\]**

On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025. The Company attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."

On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**CONTACT:  
**Danielle Peyton  
Pomerantz LLP  
\[email protected\]  
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 諾和諾德公司將在其愛爾蘭工廠生產 Wegovy | 諾和諾德公司將在愛爾蘭工廠生產 Wegovy | [Link](https://longbridge.com/en/news/275789396.md) |
| GLP-1 抗肥胖藥物在美國市場的四張圖表 | 瑞士銀行的分析師們在馬修·韋斯頓的帶領下，分析了美國 GLP-1 抗肥胖藥物市場的趨勢，重點關注 Wegovy 的新品牌處方（NBRx）。數據顯示，Wegovy 的新品牌處方趨勢強勁，新推出的 Wegovy 藥丸對其影響甚微。即將發生的關鍵 | [Link](https://longbridge.com/en/news/276280378.md) |
| Savvy Advisors Inc. 購入了諾和諾德公司 22,138 股股票 $NVO | Savvy Advisors Inc. 在第三季度將其在諾和諾德公司（Novo Nordisk A/S）的持股增加了 83.0%，收購了 22,138 股，使其總持股達到 48,824 股，價值 270 萬美元。其他機構投資者也調整了他們的 | [Link](https://longbridge.com/en/news/275761183.md) |
| 諾和諾德公司首席財務官 Karsten Munk Knudsen 出售了價值超過 830 萬丹麥克朗的股票 | 諾和諾德公司（Novo Nordisk A/S）宣佈，首席財務官卡斯滕·穆克·克努森（Karsten Munk Knudsen）於 2026 年 2 月 10 日以每股 DKK 315.60 的價格出售了 26,246 股，交易總額為 DK | [Link](https://longbridge.com/en/news/275652909.md) |
| 諾和諾德公司獲得歐洲委員會批准使用更高劑量的 Wegovy 注射劑 | 2026 年 2 月 17 日東部時間上午 9:25（MT Newswires）-- 諾和諾德公司（NVO）週二表示，歐洲委員會已批准 Wegovy 的 7.2 毫克每週一次的維持劑量，適用於肥胖成年人。諾和諾德公司表示，此次批准是基於歐洲 | [Link](https://longbridge.com/en/news/276138110.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.